MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Sorafenib
Related studies linked through entity extraction aliases.
Combination of Toripalimab and JS004 Therapy for ccRCC
- Status
- RECRUITING
- Phase
- PHASE2
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
- Status
- WITHDRAWN
- Phase
- PHASE1
Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Status
- RECRUITING
- Phase
- PHASE2
Influence of Sarcopenia in Hepatocellular Carcinoma Patients
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- N/A
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- N/A
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- N/A
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance
- Status
- UNKNOWN
- Phase
- N/A
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
- Status
- UNKNOWN
- Phase
- N/A
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
- Status
- UNKNOWN
- Phase
- N/A
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
- Status
- UNKNOWN
- Phase
- PHASE2